Microbiota and Antitumor Immunity
|Telephone||+39 02 94375171|
|Location|| Building 13 |
Via Adamello 16, Milano
The most recent estimate of microbes populating the human body is around 40 trillion, meaning that we are made of bacteria at least as much of human cells and they coexist on our body as result of a dynamic equilibrium between Darwinian competition and cooperation. There is a growing appreciation of the role of the microbiome in cancer-related outcomes and our recent work demonstrated that differential bacterial “signatures” exist in the gut of melanoma patients that responded (R) or not (NR) to immunotherapy. Building on the synergy between scientists from different backgrounds to bridge the chasm between the bench and the clinic, our lab is seeking for innovative strategies to improve cancer prevention and response to immunotherapy by manipulating the human microbiome. We are interested in molecular mechanisms that regulate the crosstalk between innate and adaptive immune system in response to modulation of the microbiome, in particular in the gut.
We are performing multiOMIC analysis and developing new ex vivo and in vivo systems to create:
- Diagnostic tools, that could by reveal high-risk subjects or potential R and NR patients, and guide subsequent prophylactic treatments or immune-based therapeutic choices.
- Personalized interventions, by combining biotic and abiotic formulations to promote cancer prevention or turn an NR in an R.
Most Relevant Publications
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
Cell Rep, 2016